The Europe Genomics In Cancer Care Market would witness market growth of 15.5% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Genomics In Cancer Care Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $3.93 billion by 2031. The UK market is exhibiting a CAGR of 14.5% during (2024 - 2031). Additionally, The France market would experience a CAGR of 16.4% during (2024 - 2031).
Genomic information allows for the personalization of chemotherapy regimens based on the genetic profile of the patient and the tumor. By identifying genetic variations that affect drug metabolism and efficacy, clinicians can tailor chemotherapy protocols to improve treatment effectiveness and reduce adverse effects, ensuring that each patient receives the most appropriate drugs.
Additionally, adoption of genomics in cancer care has significantly transformed the oncology landscape, driven personalized treatment approaches, and improved patient outcomes. Genomics is increasingly integrated into standard clinical practice as part of routine cancer care.
The high cancer rates in Europe lead to increased government funding and support for cancer research programs. European governments allocate more resources towards genomic research initiatives to understand cancer genomics and develop new treatments. Among the EU countries, the share of deaths from cancer in the total number of deaths in 2021 reached or exceeded 26.0 % in Denmark (28.2 %), Ireland (27.7 %), Slovenia (27.1 %) and the Netherlands (26.6 %). This share peaked at 30.7 % among males in Slovenia, followed by 29.5 % in Denmark.
Based on Application, the market is segmented into Diagnostics, Personalized Medicine, Drug Discovery & Development, and Research. Based on Product, the market is segmented into Instruments, Consumables, Services. Based on Technology, the market is segmented into PCR, Genome Sequencing, Microarrays, Nuclei Acid Extraction & Purification, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Genomics In Cancer Care Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $3.93 billion by 2031. The UK market is exhibiting a CAGR of 14.5% during (2024 - 2031). Additionally, The France market would experience a CAGR of 16.4% during (2024 - 2031).
Genomic information allows for the personalization of chemotherapy regimens based on the genetic profile of the patient and the tumor. By identifying genetic variations that affect drug metabolism and efficacy, clinicians can tailor chemotherapy protocols to improve treatment effectiveness and reduce adverse effects, ensuring that each patient receives the most appropriate drugs.
Additionally, adoption of genomics in cancer care has significantly transformed the oncology landscape, driven personalized treatment approaches, and improved patient outcomes. Genomics is increasingly integrated into standard clinical practice as part of routine cancer care.
The high cancer rates in Europe lead to increased government funding and support for cancer research programs. European governments allocate more resources towards genomic research initiatives to understand cancer genomics and develop new treatments. Among the EU countries, the share of deaths from cancer in the total number of deaths in 2021 reached or exceeded 26.0 % in Denmark (28.2 %), Ireland (27.7 %), Slovenia (27.1 %) and the Netherlands (26.6 %). This share peaked at 30.7 % among males in Slovenia, followed by 29.5 % in Denmark.
Based on Application, the market is segmented into Diagnostics, Personalized Medicine, Drug Discovery & Development, and Research. Based on Product, the market is segmented into Instruments, Consumables, Services. Based on Technology, the market is segmented into PCR, Genome Sequencing, Microarrays, Nuclei Acid Extraction & Purification, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Agilent Technologies, Inc.
- F.Hoffmann-La Roche Ltd.
- Danaher Corporation (Beckman Coulter, Inc.)
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- GE HealthCare Technologies, Inc.
- Quest Diagnostics Incorporated
- Revvity, Inc.
- Eurofins Scientific SE
- Hologic, Inc.
Market Report Segmentation
By Application- Diagnostics
- Personalized Medicine
- Drug Discovery & Development
- Research
- Instruments
- Consumables
- Services
- PCR
- Genome Sequencing
- Microarrays
- Nuclei Acid Extraction & Purification
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Europe Genomics In Cancer Care Market by Application
Chapter 6. Europe Genomics In Cancer Care Market by Product
Chapter 7. Europe Genomics In Cancer Care Market by Technology
Chapter 8. Europe Genomics In Cancer Care Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation (Beckman Coulter, Inc.)
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- GE HealthCare Technologies, Inc.
- Quest Diagnostics Incorporated
- Revvity, Inc.
- Eurofins Scientific SE
- Hologic, Inc.
Methodology
LOADING...
